Clinical Trial Detail

NCT ID NCT02933255
Title PROSTVAC in Combination With Nivolumab and/or Ipilimumab in Men With Prostate Cancer
Recruitment Recruiting
Gender male
Phase Phase Ib/II
Variant Requirements No
Sponsors National Cancer Institute (NCI)
Indications

prostate cancer

Therapies

Ipilimumab + PROSTVAC-F/TRICOM + PROSTVAC-V/TRICOM

Ipilimumab + Nivolumab + PROSTVAC-F/TRICOM + PROSTVAC-V/TRICOM

Nivolumab + PROSTVAC-F/TRICOM + PROSTVAC-V/TRICOM

Age Groups: senior adult

No variant requirements are available.